Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HALP Score in Predicting Post-Liver Transplant Outcomes in Patients with Hepatocellular Carcinoma.

Journal of clinical medicine·2026
Same author

Combined treatment with vitamin K2 and albumin inhibits growth in hepatocellular carcinoma cells by promoting differentiation and apoptosis.

Molecular biology reports·2026
Same author

A Network Phenotyping Strategy approach in a Turkish HCC Dataset and Comparison of Patients Selected for Transplant and those who were not.

Journal of Inonu Liver Transplantation Institute·2025
Same author

Transplant Versus Non-Transplant Hepatocellular Carcinoma Patient Characteristics And Survival.

World journal of medical oncology..·2025
Same author

A New Approach to Analysis of Clinical Data and Prognostication for Patients with Hepatocellular Carcinoma, Based Upon a Network Phenotyping Strategy (NPS) Computational Method.

Journal of Inonu Liver Transplantation Institute·2025
Same author

Mean Platelet Volume Is a Poor Prognostic Factor in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology·2025
Same journal

Upward Mobility: How Mobile Endoscopy Revolutionized Endoscopic Practice in the Developing World.

Digestive diseases and sciences·2026
Same journal

Hematologic and Inflammatory Biomarker-Based Prognostic Assessment in Acute Pancreatitis: The Role of CRP, Procalcitonin, and CRP/Albumin Ratio.

Digestive diseases and sciences·2026
Same journal

Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.

Digestive diseases and sciences·2026
Same journal

Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.

Digestive diseases and sciences·2026
Same journal

Cardiac Arrests During Inpatient Gastrointestinal Endoscopic Procedures: A United States Nationwide Assessment.

Digestive diseases and sciences·2026
Same journal

Standardizing Transition of Care for Adolescents with Inflammatory Bowel Disease: The Need for a Unified Approach.

Digestive diseases and sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

HCC in older patients.

Brian I Carr1, Petr Pancoska, Robert A Branch

  • 1Department of Medical Oncology, Liver Tumor Program, Kimmel Cancer Center, Thomas Jefferson University, Bluemle Building, Room 1002, 233 S 10th Street, Philadelphia, PA 19107, USA. brian.carr@jefferson.edu

Digestive Diseases and Sciences
|March 19, 2010
PubMed
Summary
This summary is machine-generated.

Hepatocellular carcinoma (HCC) patient survival shows age clustering. Older patients with lower alpha-fetoprotein (AFP) and bilirubin levels, and smaller tumors, survived longer, indicating these factors predict HCC prognosis.

More Related Videos

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Related Experiment Videos

Last Updated: Jun 15, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Area of Science:

  • Hepatology
  • Oncology
  • Biostatistics

Background:

  • Hepatocellular carcinoma (HCC) presents as a heterogeneous disease with poorly defined prognostic patient subgroups.
  • Identifying distinct HCC patient subsets is crucial for optimizing patient stratification and treatment selection.

Purpose of the Study:

  • To investigate survival patterns and identify prognostic patient subsets in a large cohort of unresectable and untransplantable HCC.
  • To analyze the correlation between patient demographics, liver function parameters, tumor characteristics, and survival outcomes in HCC.

Main Methods:

  • Analysis of a database of 778 biopsy-proven HCC patients followed from diagnosis to death.
  • Application of a moving average algorithm to order patients by survival and analyze survival cohorts based on liver function and CT parameters.

Main Results:

  • Significant age clustering was observed in HCC patient survival, particularly in older individuals.
  • Two distinct survival subgroups were identified in older patients: one with 45-80 days survival and another with 330-1,250 days survival.
  • Longer survival correlated with lower serum bilirubin and alpha-fetoprotein (AFP) levels, and smaller tumor mass. AFP and bilirubin trends were similar, suggesting interdependence, further supported by AFP's correlation with GGTP, ALKP, and SGOT.

Conclusions:

  • A large HCC cohort demonstrates significant age-related survival clustering, especially in elderly patients.
  • Alpha-fetoprotein (AFP), bilirubin levels, and age are interconnected factors influencing HCC severity and patient survival.